Sign In
Buy ANAB
$51.24
-0.0200 (-0.0390%)
At Close: Jun 03, 2026
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates
07:55pm, Thursday, 27'th Feb 2025
AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $1.61. This compares to loss of $1.59 per share a year ago.
Anaptys Announces Participation in March Investor Conferences
04:15pm, Thursday, 27'th Feb 2025
SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dani
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
04:15pm, Thursday, 27'th Feb 2025
Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 months Full clinical and t
Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year?
10:41am, Thursday, 13'th Feb 2025
Here is how AnaptysBio, Inc. (ANAB) and AtriCure (ATRC) have performed compared to their sector so far this year.
AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains?
06:16am, Thursday, 13'th Feb 2025
AnaptysBio (ANAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months
07:30am, Wednesday, 12'th Feb 2025
Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs. placebo Achieved statistical significance on key secondary endp
SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor cal
Anaptys to Present at the Guggenheim SMID Cap Biotech Conference
04:15pm, Monday, 03'rd Feb 2025
SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dani
Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular Psoriasis Vanda expects to immediately begin preparing BLA and MAA applications for the US and EU Anaptys to r
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?
10:41am, Monday, 27'th Jan 2025
Here is how AnaptysBio, Inc. (ANAB) and Inspire Medical Systems (INSP) have performed compared to their sector so far this year.
How AnaptysBio (ANAB) Stock Stands Out in a Strong Industry
10:46am, Monday, 13'th Jan 2025
AnaptysBio (ANAB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference
09:15am, Tuesday, 07'th Jan 2025
SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dani
AnaptysBio Stock Down as Eczema Study Fails to Meet Goals
10:05am, Thursday, 12'th Dec 2024
Phase IIb study on ANAB's ANB032 for atopic dermatitis fails to meet goals. The company decides to discontinue any further investment in the candidate.
AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data
02:07pm, Wednesday, 11'th Dec 2024
On Wednesday, AnaptysBio, Inc. ANAB announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the ARISE-AD trial as a monot
AnaptysBio to abandon eczema drug development after mid-stage trial failure
10:20am, Wednesday, 11'th Dec 2024
AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a mid-stage trial, the company said on Wednesday, dragging its shares nearly 4
